Journal: Journal of Biological Chemistry

Article Title: Role of Sphingosine-1-phosphate Phosphatase 1 in Epidermal Growth Factor-induced Chemotaxis

doi: 10.1074/jbc.m404907200

Figure Lengend Snippet: FIG. 6. SPP-1 overexpression abro- gates EGF-induced ERK 1/2 activation but not EGFR tyrosine phosphoryla- tion. HEK 293 cells stably expressing vec- tor or SPP-1 were serum-starved for 16 h and treated without or with EGF (100 ng/ ml) for 5 min. A, cells were lysed, and equal amounts of proteins were immunoprecipi- tated with anti-EGFR and analyzed by Western blotting with anti-phosphoty- rosine antibody (upper panel). Blots were then stripped and reprobed with anti- EGFR (bottom panel) as a loading control. B, equal amounts of total lysates were also analyzed by immunoblotting with an- ti-phosphotyrosine; activation of ERK (C) and p38 (D) was determined with phos- pho-specific anti-ERK1/2 and p38 anti- bodies, respectively. Blots were stripped and reprobed with ERK2 or p38 antibod- ies to demonstrate equal loading. Num- bers indicate relative intensities deter- mined by densitometry of scanned blots.

Article Snippet: AntiEGF receptor polyclonal antibody and phospho-p38 and ERK2 antibodies (Santa Cruz), phosphotyrosine monoclonal antibody 4G10 (Upstate Biotechnology, Lake Placid, NY), p38, and phospho-ERK1/2 antibodies (Cell Signaling Technology, Beverly, MA) were used as primary antibodies.

Techniques: Over Expression, Activation Assay, Stable Transfection, Expressing, Western Blot, Control

Journal: International Journal of Molecular Sciences

Article Title: p38β, A Novel Regulatory Target of Pokemon in Hepatic Cells

doi: 10.3390/ijms140713511

Figure Lengend Snippet: ( a ) Inhibition of SB202190 on cell viability: MTT assays in HepG2, BEL7404 and HL7702 cells treated with SB202190 for 48 h at different concentrations (0, 2.5, 5, 10, 25 and 50 μM); ( b ) Western blot: Displaying that SB202190 dose-dependently inhibits the phosphorylation of p38 downstream proteins. HepG2 cells were treated with SB202190 for 24 h at different concentrations (0, 10, 25 and 50 μM); ( c – g ) HepG2 cells were treated with 25 μM SB202190 at 24 h after transfecting with pcDNA3.1(−)-Pokemon or pcDNA3.1(−): ( c ) HepG2 Cell growth rate; ( d ) Effect of Pokemon and p38 inhibitor SB202190 on colony formation in HepG2 cells, the colony formation rate stands for the proportion of final clone number accounted for in plated cell number; ( e ) In vitro migration assays; ( f ) In vitro invasion assays. Bar chart below the photo stands for the relative fold of the migrated or invaded cell number compared to the negative control group; ( g ) Pokemon activates p38 signaling pathway in hepatic cells: Left panel is Western blot bands. Western blot in HepG2 cells after Pokemon was overexpressed for 60 h, and the cells were treated by SB202190 at the concentration of 25 μM; right panel is quantification of western blot data. * p < 0.05 compared to the negative control group.

Article Snippet: Antibodies used are as follows: Pokemon antibody (Sigma, St. Louis, MO, USA), p38α MAPK (7D6) Rabbit mAb (CST, Danvers, MA, USA), p38β MAPK (c28c2) Rabbit mAb (CST), Phospho-p38 MAPK Pathway Sampler Kit (CST) and Actin antibody (Beyotime, Shanghai, China).

Techniques: Inhibition, Western Blot, Phospho-proteomics, In Vitro, Migration, Negative Control, Concentration Assay

Journal: International Journal of Molecular Sciences

Article Title: p38β, A Novel Regulatory Target of Pokemon in Hepatic Cells

doi: 10.3390/ijms140713511

Figure Lengend Snippet: Pokemon up-regulates p38β expression in hepatic cells. Pokemon was delivered by expression plasmid pcDNA3.1(−)-Pokemon with pcDNA3.1(−) as a negative control. Pokemon silencing was triggered by si-RNA. ( a ) Targeted expression or silencing of Pokemon in HepG2 cells. Cells were collected at 60 h after transfection or silencing (Left panel). And the quantification of western blot data was displayed on the Right panel; ( b ) Real-time quantitative polymerase chain reaction (qPCR) at 48 h after transfection in HepG2 cells. Upper panel: Ectopic expression of Pokemon; lower panel: Silencing of Pokemon; ( c ) Ectopic expression of Pokemon in HL7702 cells. Upper panel: Western blot in which cells were lysed and total proteins were collected at 36, 48, 60 and 72 h, respectively. Lower panel: Real-time qPCR at 48 and 60 h after transfection; ( d ) Silencing of Pokemon in BEL7404 cells. Upper panel: Western blot; lower panel: Real-time qPCR. * p < 0.05 compared to the negative control. N.C. means negative control.

Article Snippet: Antibodies used are as follows: Pokemon antibody (Sigma, St. Louis, MO, USA), p38α MAPK (7D6) Rabbit mAb (CST, Danvers, MA, USA), p38β MAPK (c28c2) Rabbit mAb (CST), Phospho-p38 MAPK Pathway Sampler Kit (CST) and Actin antibody (Beyotime, Shanghai, China).

Techniques: Expressing, Plasmid Preparation, Negative Control, Transfection, Western Blot, Real-time Polymerase Chain Reaction

Journal: International Journal of Molecular Sciences

Article Title: p38β, A Novel Regulatory Target of Pokemon in Hepatic Cells

doi: 10.3390/ijms140713511

Figure Lengend Snippet: Pokemon stimulates p38β promoter activity. ( a ) ChIP assays in HepG2 and BEL7404 cells. Protein-DNA complexes are immunoprecipitated either with anti-Pokemon antibody or anti-IgG as negative control, followed by PCR with primers specific to p38β promoter sequence and agarose-gel electrophoresis for visualization. Total lysates were used as the input samples and positive control; ( b ) Dual luciferase reporter assay. Luciferase activities were normalized to Renilla activity. Y axis stands for the relative fold changes of activity as the pcDNA3.1(−)-Pokemon plasmid increases. * p < 0.05 compared to the negative control.

Article Snippet: Antibodies used are as follows: Pokemon antibody (Sigma, St. Louis, MO, USA), p38α MAPK (7D6) Rabbit mAb (CST, Danvers, MA, USA), p38β MAPK (c28c2) Rabbit mAb (CST), Phospho-p38 MAPK Pathway Sampler Kit (CST) and Actin antibody (Beyotime, Shanghai, China).

Techniques: Activity Assay, Immunoprecipitation, Negative Control, Sequencing, Agarose Gel Electrophoresis, Positive Control, Luciferase, Reporter Assay, Plasmid Preparation

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Hibiscus sabdariffa L.: A potent natural neuroprotective agent for the prevention of streptozotocin-induced Alzheimer's disease in mice.

doi: 10.1016/j.biopha.2020.110303

Figure Lengend Snippet: Fig. 6. Effects of Hibiscus extracts and celecoxib on the activity of p38MAPK (A), and COX-2 (B), and on concentration of mPGES-1 (C) and PGE2 (D). p38MAPK and COX-2 levels in celecoxib (30 mg/kg), white and red Hibiscus (200 mg/kg each) groups were decreased compared to STZ (3 mg/kg, ICV) group and increased compared to the normal group. mPGES-1 and PGE2levels were normalized in the three treated groups. Panel 4 represents immunoblot analysis shown in Fig. 6.A. Panel 5 represents immunoblot analysis shown in Fig. 6.B. Data are expressed as means ± S.D. The significance of the dif- ference between means was tested by ANOVA followed by Tukey Kramer multiple compar- isons test. * P < 0.05 vs normal; @ P < 0.05 vs STZ-treated group; # P < 0.05 vs celecoxib. n = 6 mice, DF = 29. For p38MAPK: F = 354.1, R2 = 0.9827. For COX-2: F = 350.5, R2 = 0.9825. For m-PGES-1: F = 430.4, R2 = 0.9857. For PGE2: F = 354.3, R2 = 0.9827.

Article Snippet: The antibodies used were rabbit BACE1 monoclonal [EPR19523] (abcam, ab183612), mouse Cox-2 (H-3) monoclonal (Santa cruze Inc, sc-376861), rabbit PSENEN polyclonal (Boster Biological Technology, A04504) and rabbit p38 MAPK polyclonal (Biorbyt Ltd., orb127559).

Techniques: Activity Assay, Concentration Assay, Western Blot